Pfizer

AbbVie

Johnson & Johnson

Bristol-Myers

Merck

United Therapeutics

Amgen

Eli Lilly

Regeneron Pharmaceuticals

Gilead Sciences

First Trust Nasdaq Pharmaceuticals ETF 

FTXH tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth.

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Solid Q2 Earnings

A Look at Pharma ETFs Post Q1 Earnings

iShares U.S. Healthcare ETF

Health Care Select Sector SPDR Fund

Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.

JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Pharma ETFs in Focus Post Q3 Earnings

Kenvue

Vanguard Health Care ETF

The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Pharma ETFs in Focus Post Q2 Earnings

Hawaiian Electric Industries

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.

5 ETFs to Buy on JNJ's Q2 Earnings Strength

VanEck Vectors Biotech ETF

First Trust Morningstar Dividend Leaders Index Fund

Amplify Treatments Testing & Advancements ETF

iShares Core High Dividend ETF

Invesco Nasdaq Biotechnology ETF

Horizon Kinetics Medical ETF

Moderna

Novavax

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.

Pharma ETFs Gain Post Q1 Earnings

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

A Look at Pharma ETFs Post Q4 Earnings

This healthcare ETF hits a new 52-week high. Are more gains in store for this ETF?

Healthcare ETF (FTXH) Hits New 52-Week High

Global X Longevity Thematic ETF 

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Global X Genomics & Biotechnology ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco S&P SmallCap Health Care ETF

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

ALPS Medical Breakthroughs ETF

Wisdomtree BioRevolution Fund

SPDR S&P Biotech ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

First Trust Nasdaq Food & Beverage ETF 

Invesco S&P 500 Equal Weight Utilities ETF

Energy Select Sector SPDR Fund

SPDR S&P Metals & Mining ETF

Here are the top-performing sector ETFs of 2022. These include energy, healthcare, materials, utilities and consumer staples.

5 Best Sector ETFs of 2022

Horizon Pharma

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.

2 Sector ETFs Hovering Around a 52-Week High

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q1 Earnings

GlaxoSmithKline

Sanofi

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Solid Q4 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

Pharma ETFs Gain on Q2 Earnings

Direxion Daily Healthcare Bull 3x Shares

abrdn Healthcare Investors 

abrdn Life Sciences Investors 

Defiance Nasdaq Junior Biotechnology ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

ProShares UltraShort Health Care

ProShares Ultra Health Care

Pacer BioThreat ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

iShares Evolved U.S. Innovative Healthcare ETF

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

LeMaitre Vascular

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.

Healthcare: A Wide Choice Of Large And Well-Established Companies

News for First Trust Nasdaq Pharmaceuticals ETF ETF (FTXH)